New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 24, 2014
06:23 EDTBAYRYBayer extends offer for Algeta takeover offer
The Bayer Group is extending the offer period for the voluntary takeover offer for Norwegian pharmaceutical company Algeta ASA, Oslo, by two days to February 26 at 09:00 CET. Except for the extension of the offer period, all other terms and conditions of the offer remain unchanged. Bayer is offering NOK 362 in cash per share for all issued Algeta shares. As of February 24 at 7:40 CET, Bayer had received acceptances and pre-acceptances of the offer for approximately 40,485,490 shares, representing approximately 92.17 % of Algeta's share capital in response to its voluntary takeover offer. The acceptance level is based on preliminary numbers and may be subject to adjustments. Currently, Bayer does not own any shares in Algeta ASA. All regulatory approvals required for completion of the proposed acquisition have been obtained. However, the offer is still subject to certain closing conditions, which are set out in the offer document published on January 20. These stipulate, among other things, that at least 90 % of Algeta's share capital must be tendered to Bayer. It remains to be verified by means of the final acceptance numbers that this condition is satisfied. Bayer maintains its right to further extend the offer period as set out in the offer document. Subject to the fulfillment or waiver of all offer conditions, Bayer expects to complete the acquisition in the first quarter of 2014.
News For BAYRY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2014
11:34 EDTBAYRYMerck completes sale of Consumer Care business to Bayer $14.2B
Merck (MRK) said it has completed the previously announced sale of the Merck Consumer Care business to Bayer (BAYRY). Bayer will acquire Merck’s existing over-the-counter business, including the global trademark and prescription rights for CLARITINTM and AFRINTM, for $14.2B or approximately $9B in after-tax proceeds, less customary closing adjustments as well as certain contingent amounts held back that will be payable upon the manufacturing site transfer in Canada and regulatory approvals in Mexico and Korea. In conjunction with this transaction, Merck has also entered into the previously announced worldwide collaboration between the companies to develop and commercialize soluble guanylate cyclase modulators. This collaboration includes Bayer’s ADEMPASTM. The collaboration also includes opt-in rights for other early-stage sGC compounds in development by both companies. Merck will be making an upfront payment of $1B in connection with the sGC collaboration.
September 30, 2014
12:12 EDTBAYRYOncoMed cancer pipeline expanded with new candidate, says Piper Jaffray
Subscribe for More Information
08:37 EDTBAYRYOncoMed announces advancement small molecule Wnt pathway inhibitor
Subscribe for More Information
September 25, 2014
11:25 EDTBAYRYBayer said to not plan spin-off of Agrochem unit, Bloomberg reports
Subscribe for More Information
September 23, 2014
09:00 EDTBAYRYBofa/Merill special situations team to hold an analyst/industry conference call
Subscribe for More Information
September 22, 2014
05:17 EDTBAYRYRegeneron announces EYLEA injection approved for myopic CNV treatment in Japan
Subscribe for More Information
September 19, 2014
07:35 EDTBAYRYZoetis seen as potential Bayer target after split announcement, Bloomberg says
Subscribe for More Information
September 18, 2014
06:20 EDTBAYRYBayer to float MaterialScience as separate company
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use